NCT01215903

Brief Summary

The present study was conducted to test whether a fish gelatin supplement combined with an omega-3 polyunsaturated fatty acid supplement can exert beneficial and sex-specific effects on insulin sensitivity, glucose tolerance, indicators of insulin secretion, blood pressure, lipid metabolism, inflammation and energy intake in obese or overweight insulin-resistant men and women. The investigators hypothesis is that fish gelatin improves insulin sensitivity, glucose tolerance, lipid profile and reduces inflammation in obese or overweight insulin-resistant men and women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Nov 2007

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2009

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

October 5, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 7, 2010

Completed
Last Updated

October 25, 2010

Status Verified

October 1, 2010

Enrollment Period

1.5 years

First QC Date

October 5, 2010

Last Update Submit

October 22, 2010

Conditions

Outcome Measures

Primary Outcomes (4)

  • Insulin sensitivity

    At 8 weeks

  • Plasma lipids and lipoproteins

    at 8 weeks

  • Blood pressure

    At 8 weeks

  • Plasma and serum inflammatory markers

    At 8 weeks

Secondary Outcomes (3)

  • Glucose tolerance

    At 8 weeks

  • Energy intake

    At 8 weeks

  • Fatty acids of phospholipids in skeletal muscle

    At 8 weeks

Study Arms (2)

Fish gelatin and omega-3

EXPERIMENTAL
Dietary Supplement: Fish gelatin and omega-3 polyunsaturated fatty acid

Omega-3

EXPERIMENTAL
Dietary Supplement: Omega-3 polyunsaturated fatty acid

Interventions

Fish gelatin and omega-3
Omega-3

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • overweight or obese (body mass index \[BMI\] between 25 and 40kg/m2)
  • fasting plasma glucose below 7.0mmol/L and 2-h plasma glucose below 11.1mmol/L
  • fasting plasma insulin above 90pmol/L

You may not qualify if:

  • Diabetes, chronic, metabolic or acute disease
  • Major surgery within the last 3 months
  • Significant weight loss (±10%) within the last 6 months
  • Any medication-taking known to affect lipid of glucose metabolism
  • Allergy, intolerance or dislike of fish
  • Smokers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Laval University

Québec, Quebec, G1V 0A6, Canada

Location

MeSH Terms

Conditions

Insulin ResistanceDiabetes Mellitus, Type 2

Interventions

Docosahexaenoic Acids

Condition Hierarchy (Ancestors)

HyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesDiabetes MellitusEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Fatty Acids, Omega-3Dietary Fats, UnsaturatedDietary FatsFatsLipidsFatty Acids, UnsaturatedFatty AcidsFish OilsOils

Study Officials

  • Helene Jacques, PhD

    Laval University

    PRINCIPAL INVESTIGATOR
  • Andre Marette, PhD

    Laval University

    PRINCIPAL INVESTIGATOR
  • John S Weisnagel, MD/FRCPC

    Laval University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 5, 2010

First Posted

October 7, 2010

Study Start

November 1, 2007

Primary Completion

May 1, 2009

Study Completion

May 1, 2009

Last Updated

October 25, 2010

Record last verified: 2010-10

Locations